Mounjaro®
Starting from £179.99/mo
Start journey Learn moreLosing 3 stone on Wegovy — roughly 19 kg — is within the range seen in clinical trials, but it is not a fixed timeline. Most people who reach that level of weight loss do so somewhere between 12 and 18 months of treatment, though individual results vary considerably depending on starting weight, dose, lifestyle changes and how the body responds. Wegovy (semaglutide) is a prescription-only medicine; a prescriber assesses whether it is clinically appropriate for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
One of the most common assumptions about Wegovy is that a dramatic loss happens quickly. Social media accounts and anecdotal posts create the impression that 3 stone falls off within a matter of weeks. The published evidence tells a different story, and understanding it honestly sets you up for a far better experience.
The STEP 1 clinical trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks. Participants lost an average of around 15% of their starting body weight at the 2.4 mg dose. For someone starting at 20 stone, that translates to approximately 3 stone. The trial ran for 68 weeks (a little over 15 months) and that figure represents an average across the whole group, not a minimum or a guarantee.
Some people lost considerably more. Others lost less. A 3-stone target sits at the higher end of what an average person might expect, which is why understanding how long each stone of loss typically takes on Wegovy helps set a more realistic picture of the full timeline. If you want a more grounded sense of what weight loss looks like earlier in treatment, this piece on the early weeks breaks down what to expect once you start.
The honest framing: 3 stone is an achievable but ambitious goal, and patience with the process is not a bug in the plan, it is the plan.
Wegovy does not begin at its full strength. Treatment starts at 0.25 mg, moving through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance dose, with roughly four weeks at each level. That means you spend approximately 16 to 20 weeks climbing to the dose at which the strongest appetite-suppressing effect is established.
Weight loss can and does begin during this titration period, many people notice reduced appetite and some early loss within the first month. But the rate accelerates once the maintenance dose is reached and the body settles into it. A practical checking habit: track your weight every two weeks at the same time of day and note it down somewhere simple. That pattern, not any single weigh-in, is what tells you whether treatment is working as expected.
The full picture of how long Wegovy takes to work explains the mechanism behind this gradual build. The short version is that semaglutide works by slowing gastric emptying and reducing appetite signals; those effects compound over time as the dose increases and the body adjusts. Expecting 3 stone to disappear before you have even reached full dose is the most common source of early disappointment, and often the reason some people stop too soon.
NHS guidance on weight management injections notes that stopping treatment is considered if less than 5% weight loss is achieved after six months at the maintenance dose. That threshold is a clinical marker, not a personal verdict, context and clinical review both matter here.
Weight loss on semaglutide typically follows a recognisable curve. The first three months often produce the fastest visible progress; appetite reduction can be pronounced and calorie intake drops significantly. After that, the rate tends to slow as the body recalibrates its energy balance, even while weight continues to fall. This is not a plateau in the clinical sense, it is the natural pace of sustained loss.
For context, two stone of loss is something many people achieve within the first eight to twelve months; the additional stone beyond that typically takes longer per unit of weight because the deficit narrows as body composition changes. Strength-preserving activity and adequate protein become increasingly important in this phase, both to protect muscle and to support continued loss. Your prescriber is the right person to discuss how to structure that alongside treatment.
People starting at a higher body weight (say, 22 stone or above) may reach 3 stone sooner in absolute terms because the early percentage losses translate to larger absolute amounts. Those starting closer to 15 stone may find that 3 stone represents a higher percentage of their body weight and takes longer. How long weight loss takes on Wegovy overall covers the broader patterns in more detail.
For questions about what it costs to access Wegovy privately while working towards a goal like this, the Wegovy cost page sets out what private treatment typically involves. And if you would like to understand the full treatment landscape before deciding anything, the treatment overview is a good starting point.
Individual variation in response to semaglutide is real and well-documented. Several factors influence how quickly (or whether) a 3-stone loss is reached. Starting body weight matters: a larger starting weight tends to mean larger absolute losses in the same timeframe. Adherence to the reduced-calorie diet that accompanies treatment matters too; Wegovy is licensed as an adjunct to lifestyle changes, not a standalone fix.
Genetic variation in GLP-1 receptor sensitivity means some people experience stronger appetite suppression than others at the same dose. That is not something adjustable by willpower, and it is not a reason to assume treatment is failing if your progress looks different from someone else's.
Side effects can affect progress indirectly. Nausea, which is common particularly after dose increases, sometimes makes eating any structured diet feel difficult. Most people find this settles within a few weeks, but it can temporarily distort the picture. The point to hold onto is that slower progress during the titration phase does not predict the overall result.
Clinical oversight is part of how you stay on track safely. Our clinical team reviews progress before every repeat, meaning any concerns about pace, side effects or suitability are addressed by a real prescriber, not left to guesswork. If you would like to explore whether Wegovy is clinically appropriate for you, speaking to our prescribers is where that conversation starts.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.